NASDAQ:MRTXMirati Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mirati Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $138.75 +0.87 (+0.63 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$135.29Now: $138.75▼$138.7950-Day Range$113.26MA: $120.64▼$131.5952-Week Range$66.01Now: $138.75▼$138.79Volume248,315 shsAverage Volume516,301 shsMarket Capitalization$6.18 billionP/E RatioN/ADividend YieldN/ABeta1.79 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 1.4 Analyst's Opinion Consensus RatingMirati Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.77, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $123.17, Mirati Therapeutics has a potential downside of 11.2% from its current price of $138.75.Amount of Analyst CoverageMirati Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesMirati Therapeutics has received 394 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMirati Therapeutics has received 291 “underperform” votes. (Add your “underperform” vote.)Community SentimentMirati Therapeutics has received 57.52% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote “Outperform” if you believe MRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMirati Therapeutics does not currently pay a dividend.Dividend GrowthMirati Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirati Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,713,800.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Mirati Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mirati Therapeutics are expected to decrease in the coming year, from ($8.70) to ($8.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirati Therapeutics is -19.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirati Therapeutics is -19.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirati Therapeutics has a P/B Ratio of 14.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.86 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRTX Previous Symbol CUSIPN/A CIK1576263 Webwww.mirati.com Phone858-332-3410Debt Debt-to-Equity RatioN/A Current Ratio12.57 Quick Ratio12.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.34 million Price / Sales1,850.32 Cash FlowN/A Price / Cash FlowN/A Book Value$9.67 per share Price / Book14.35Profitability EPS (Most Recent Fiscal Year)($5.69) Net Income$-213,260,000.00 Net Margins-10,983.84% Return on Equity-60.32% Return on Assets-54.97%Miscellaneous Employees63 Outstanding Shares44,541,000Market Cap$6.18 billion Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $138.75 +0.87 (+0.63 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MRTX News and Ratings via Email Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions How has Mirati Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRTX stock has increased by 79.3% and is now trading at $138.75. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Mirati Therapeutics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mirati Therapeutics. When is Mirati Therapeutics' next earnings date? Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Mirati Therapeutics. How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics Inc (NASDAQ:MRTX) released its earnings results on Thursday, May, 7th. The biotechnology company reported ($2.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.66) by $0.36. The biotechnology company earned $0.27 million during the quarter, compared to analysts' expectations of $0.29 million. Mirati Therapeutics had a negative net margin of 10,983.84% and a negative return on equity of 60.32%. Mirati Therapeutics's quarterly revenue was down 78.5% compared to the same quarter last year. View Mirati Therapeutics' earnings history. What price target have analysts set for MRTX? 13 Wall Street analysts have issued 12 month price objectives for Mirati Therapeutics' shares. Their forecasts range from $83.00 to $163.00. On average, they expect Mirati Therapeutics' share price to reach $123.17 in the next year. This suggests that the stock has a possible downside of 11.2%. View analysts' price targets for Mirati Therapeutics. Has Mirati Therapeutics been receiving favorable news coverage? Media coverage about MRTX stock has been trending somewhat negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mirati Therapeutics earned a news impact score of -1.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the next few days. View the latest news about Mirati Therapeutics. Are investors shorting Mirati Therapeutics? Mirati Therapeutics saw a drop in short interest in May. As of May 29th, there was short interest totaling 5,150,000 shares, a drop of 14.2% from the May 14th total of 6,000,000 shares. Based on an average daily volume of 562,200 shares, the short-interest ratio is presently 9.2 days. View Mirati Therapeutics' Short Interest. Who are some of Mirati Therapeutics' key competitors? Some companies that are related to Mirati Therapeutics include Genmab A/S (GNMSF), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), BioMarin Pharmaceutical (BMRN), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN) and Dr.Reddy's Laboratories (RDY). View all competitors. What other stocks do shareholders of Mirati Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), salesforce.com (CRM), Square (SQ), Alibaba Group (BABA), Splunk (SPLK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Etsy (ETSY) and AbbVie (ABBV). Who are Mirati Therapeutics' key executives? Mirati Therapeutics' management team includes the following people: Dr. Charles M. Baum, Pres, CEO & Director (Age 61)Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)Temre Johnson, Director of Investor Relations & Corp. Communications What is Mirati Therapeutics' stock symbol? Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX." Who are Mirati Therapeutics' major shareholders? Mirati Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.74%), FMR LLC (4.65%), Orbimed Advisors LLC (2.97%), RTW Investments LP (2.44%), Jennison Associates LLC (1.16%) and Cormorant Asset Management LP (1.12%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Henry J Fuchs, Isan Chen, Jamie A Donadio, Ltd Braslyn, Michael G Grey and Venbio Select Advisor Llc. View institutional ownership trends for Mirati Therapeutics. Which institutional investors are selling Mirati Therapeutics stock? MRTX stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, FMR LLC, Orbimed Advisors LLC, Jennison Associates LLC, Holocene Advisors LP, Deerfield Management Company L.P. Series C, Victory Capital Management Inc., and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Mirati Therapeutics company stock in the last year include Bruce L A Carter, Charles M Baum, Craig A Johnson, Henry J Fuchs, Isan Chen, Ltd Braslyn, and Michael G Grey. View insider buying and selling activity for Mirati Therapeutics. Which institutional investors are buying Mirati Therapeutics stock? MRTX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Federated Hermes Inc., RTW Investments LP, Assenagon Asset Management S.A., Man Group plc, Vanguard Group Inc., Edmond DE Rothschild Holding S.A., and Columbus Circle Investors. View insider buying and selling activity for Mirati Therapeutics. How do I buy shares of Mirati Therapeutics? Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mirati Therapeutics' stock price today? One share of MRTX stock can currently be purchased for approximately $138.75. How big of a company is Mirati Therapeutics? Mirati Therapeutics has a market capitalization of $6.18 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe. What is Mirati Therapeutics' official website? The official website for Mirati Therapeutics is www.mirati.com. How can I contact Mirati Therapeutics? Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
